Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.

BACKGROUND & AIMS Endoscopic screening and periodic surveillance for patients with Barrett's esophagus has been shown to be cost-effective in patients with esophageal dysplasia, with treatment for esophageal cancer limited to esophagectomy. Most gastroenterologists refer patients with high-grade dysplasia for esophagectomy, and effective endoscopic therapies are available for nonoperative patients with esophageal cancer. The cost-effectiveness of screening strategies that incorporate these nonsurgical treatment modalities has not been determined. METHODS We designed a Markov model to compare lifetime costs and life expectancy for a cohort of 50-year-old men with chronic reflux symptoms. We compared 10 clinical strategies incorporating combinations of screening and surveillance protocols (no screening, screening with periodic surveillance for both dysplastic and nondysplastic Barrett's esophagus, or periodic surveillance for dysplasia only), treatment for high-grade dysplasia (esophagectomy or intensive surveillance), and treatment for cancer (esophagectomy or surgical and endoscopic treatment options). RESULTS Screening and surveillance of patients with both dysplastic and nondysplastic Barrett's esophagus followed by esophagectomy for surgical candidates with high-grade dysplasia or esophageal cancer and endoscopic therapy for cancer patients who were not operative candidates cost $12,140 per life-year gained compared to no screening. Other screening strategies, including strategies that had no endoscopic treatment options, were either less effective at the same cost, or equally effective at a higher cost. CONCLUSIONS The cost-effectiveness of screening and subsequent surveillance of patients with dysplastic as well as nondysplastic Barrett's esophagus followed by endoscopic or surgical therapy in patients who develop cancer compares favorably to many widely accepted screening strategies for cancer.

[1]  T. Eisenbach,et al.  Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. , 2001, Gastrointestinal endoscopy.

[2]  F. Ellis,et al.  Barrett's esophagus. Prevalence and incidence of adenocarcinoma. , 1991, Archives of internal medicine.

[3]  R. Heitmiller,et al.  Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. , 1996, Annals of surgery.

[4]  The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry , 1999 .

[5]  F. Ellis,et al.  Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. , 1997, The Journal of thoracic and cardiovascular surgery.

[6]  P. D. De Leyn,et al.  Surgical treatment of Barrett's carcinoma. Correlations between morphologic findings and prognosis. , 1994, The Journal of thoracic and cardiovascular surgery.

[7]  A R Zinsmeister,et al.  Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. , 1993, Gastroenterology.

[8]  P. Pairolero,et al.  High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. , 2002, The Annals of thoracic surgery.

[9]  P. Devitt,et al.  Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery. , 2004, Gastrointestinal endoscopy.

[10]  G. Falk.  Endoscopic surveillance of Barrett's esophagus , 2000 .

[11]  L. Gossner,et al.  Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. , 2000, Gastroenterology.

[12]  J. BotellaLlusiá,et al.  [Long-term results]. , 1983, Anales de la Real Academia Nacional de Medicina.

[13]  C. Reed,et al.  Chemotherapy, radiation therapy, and resection for carcinoma of the esophagus. Long-term results. , 1989, The Journal of thoracic and cardiovascular surgery.

[14]  M. Sabel,et al.  Adenocarcinoma of the esophagus with and without Barrett mucosa. , 2000, Archives of surgery.

[15]  Prateek Sharma,et al.  Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma , 2002, American Journal of Gastroenterology.

[16]  D. Castell,et al.  Symptomatic gastroesophageal reflux: Incidence and precipitating factors , 1976, The American Journal of Digestive Diseases.

[17]  A. Fendrick,et al.  Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A CostUtility Analysis , 2003, Annals of Internal Medicine.

[18]  H. Bosworth,et al.  Quality of life in patients with Barrett's esophagus undergoing surveillance. , 2002 .

[19]  F. Ellis,et al.  Endoscopic surveillance of Barrett's esophagus. Does it help? , 1993, The Journal of thoracic and cardiovascular surgery.

[20]  H. El‐Serag,et al.  Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA , 2002, Gut.

[21]  B. Overholt,et al.  Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. , 1999, Gastrointestinal endoscopy.

[22]  S. Pauker,et al.  The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.

[23]  E. Furth,et al.  Efficacy, safety, and clinical outcomes of endoscopic mucosal resection: a study of 101 cases. , 2002, Gastrointestinal endoscopy.

[24]  L. Bonavina,et al.  Results of Surgical Therapy in Patients with Barrett’s Adenocarcinoma , 2003, World Journal of Surgery.

[25]  Prateek Sharma,et al.  Long-term follow-up of Barrett's high-grade dysplasia , 2000, American Journal of Gastroenterology.

[26]  R. M. Stewart,et al.  Complications of surgical endoscopy , 1997, Surgical Endoscopy.

[27]  J. Goldblum,et al.  The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression , 2000, American Journal of Gastroenterology.

[28]  P. Lavori,et al.  Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. , 2001 .

[29]  Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? , 2000 .

[30]  D. Eddy.  Screening for breast cancer. , 1989, Annals of internal medicine.

[31]  C. Begg,et al.  Impact of hospital volume on operative mortality for major cancer surgery. , 1998, JAMA.

[32]  M. Fahs,et al.  The cost-effectiveness of cervical cancer screening for low-income elderly women. , 1988, JAMA.

[33]  B. Overholt,et al.  Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation , 2000, American Journal of Gastroenterology.

[34]  R. Sandler,et al.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.

[35]  A. Zaman,et al.  Unsedated Peroral Endoscopy With a Video Ultrathin Endoscope: Patient Acceptance, Tolerance, and Diagnostic Accuracy , 1998, American Journal of Gastroenterology.

[36]  Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. , 1996 .

[37]  T. Rice,et al.  Surgical management of high-grade dysplasia in Barrett's esophagus. , 1993, The American journal of gastroenterology.

[38]  B. Overholt,et al.  Photodynamic therapy for Barrett's esophagus. , 1997, Gastrointestinal endoscopy clinics of North America.

[39]  J. Peters,et al.  Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. , 1994, The Journal of thoracic and cardiovascular surgery.

[40]  J. Birkmeyer,et al.  Hospital Volume and Surgical Mortality in the United States , 2002 .

[41]  L. Melton,et al.  Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota , 2001, Gut.

[42]  W S Payne,et al.  The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. , 1985, The New England journal of medicine.

[43]  N. Walker,et al.  Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. , 1991, Gut.

[44]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[45]  D. Corley,et al.  Marked Multi-Ethnic Variation of Esophageal and Gastric Cardia Carcinomas within the United States , 2004, American Journal of Gastroenterology.

[46]  U. Ladabaum,et al.  Barrett's Esophagus with High-Grade Dysplasia , 1999 .

[47]  A. Sonnenberg,et al.  Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. , 2001, Gastroenterology.

[48]  Tammy O. Tengs,et al.  Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[49]  S. Re,et al.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997 .

[50]  John A. Cowan,et al.  Surgical volume and quality of care for esophageal resection: do high-volume hospitals have fewer complications? , 2003, The Annals of thoracic surgery.

[51]  O. Cummings,et al.  Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. , 2003, Gastroenterology.

[52]  P. Sharma.  Controversies in Barrett's esophagus: management of high grade dysplasia. , 2001, Seminars in gastrointestinal disease.

[53]  W. Townsend,et al.  Unsedated transnasal endoscopy accurately detects Barrett's metaplasia and dysplasia. , 2002, Gastrointestinal endoscopy.

[54]  H. Koop.  Reflux Disease and Barrett's Esophagus , 2000, Endoscopy.

[55]  R. Cestari,et al.  Long-term endoscopic surveillance of patients with Barrett's esophagus. incidence of dysplasia and adenocarcinoma: a prospective study , 2003, American Journal of Gastroenterology.

[56]  W G Doos,et al.  Adenocarcinoma and Barrett's esophagus. An overrated risk? , 1984, Gastroenterology.

[57]  A. Bhattacharyya,et al.  Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. , 1997, The American journal of gastroenterology.

[58]  N. Altorki,et al.  High Grade Dysplasia: Surveillance, Mucosal Ablation, or Resection? , 2003, World Journal of Surgery.

[59]  J. Devière,et al.  Argon Plasma Coagulation in the Treatment of Barrett’s High-Grade Dysplasia and In Situ Adenocarcinoma , 2001, Endoscopy.

[60]  Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma , 1999 .

[61]  E. Arias,et al.  United States life tables, 2000. , 2002, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[62]  A. Ruol,et al.  Oesophageal resection for high‐grade dysplasia in Barrett's oesophagus , 2000, The British journal of surgery.

[63]  C. Schmitt,et al.  Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. , 1999 .

[64]  David F. Cruess,et al.  Barrett's esophagus: A prevalent, occult complication of gastroesophageal reflux disease , 1987 .

[65]  A. Schned,et al.  The Development of Dysplasia and Adenocarcinoma During Endoscopic Surveillance of Barrett’s Esophagus , 1998 .

[66]  T. Lerut,et al.  Surgical treatment of Barrett's carcinoma , 1994 .

[67]  G. Lapertosa,et al.  Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme , 1997, European journal of gastroenterology & hepatology.

[68]  Masoud Panjehpour,et al.  Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. , 2003, Gastrointestinal endoscopy.

[69]  R. Fitzgerald,et al.  Rigorous Surveillance Protocol Increases Detection of Curable Cancers Associated with Barrett's Esophagus , 2001, Digestive Diseases and Sciences.

[70]  M. Mayo,et al.  Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia , 2000, Gut.

[71]  L. Gossner,et al.  Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach , 2002, European journal of gastroenterology & hepatology.

[72]  B. Jacobson,et al.  The Indications, Utilization and Safety of Gastrointestinal Endoscopy in an Extremely Elderly Patient Cohort , 2001, Endoscopy.

[73]  L. Bonavina,et al.  Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus , 2002, Surgical Endoscopy And Other Interventional Techniques.

[74]  M. Helfand,et al.  Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. , 1997, The American journal of gastroenterology.

[75]  Noel S Weiss,et al.  Surveillance and survival in Barrett's adenocarcinomas: a population-based study. , 2002, Gastroenterology.

[76]  A. Sonnenberg,et al.  Cost-Effectiveness of Colonoscopy in Screening for Colorectal Cancer , 2000, Annals of Internal Medicine.

[77]  R. Wong,et al.  Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. , 1999, Gastroenterology.

[78]  J. Richardson,et al.  The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. , 1996, Annals of surgery.

[79]  C. Sugawa,et al.  Endoscopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy Survey. , 1976, JAMA.

[80]  B. Krevsky,et al.  Predictors of recurrent specialized intestinal metaplasia after complete laser ablation , 2003, American Journal of Gastroenterology.

[81]  R. Goyal,et al.  The histologic spectrum of Barrett's esophagus. , 1976, The New England journal of medicine.

[82]  G. Falk.  Endoscopic surveillance of Barrett's esophagus: risk stratification and cancer risk. , 1999, Gastrointestinal endoscopy.

[83]  A. Csendes,et al.  Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. , 2000, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[84]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[85]  P. Kerlin,et al.  Barrett's esophagus: clinical, endoscopic, and histologic spectrum in fifty patients. , 1986, Australian and New Zealand journal of medicine.

[86]  Paul Fockens,et al.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. , 2002, The New England journal of medicine.

[87]  G. Triadafilopoulos,et al.  Reasons for current practices in managing Barrett's esophagus. , 2002, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[88]  M. Raimondo,et al.  Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. , 2002, Mayo Clinic proceedings.